Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 142 participants.
Also called NCT01798238
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 142 participants
- Sponsor
- Registry
-
NCT01798238
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT01798238. Randomized; double masking; primary purpose treatment. Start 2012-11 (registry gives no type); primary completion 2014-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- MP-513
- Intervention (Drug)
- Placebo
- Lead sponsor
- Handok Inc.
Record details
- Record id
cardio:ct-nct01798238- Content hash
d7f9617ce6dcb473147c3a0b6c57d1010981856a96e5bb14c33d2e72e05ccf4d